This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2024
APCCC 2024
EAU 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Bladder Cancer
Viewing 21-40 of 46 articles
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Circulating Tumor Cells
ASCO GU 2020: Best of Journals Bladder Cancer - Surgery
ASCO GU 2020: Rucaparib for Recurrent, Locally Advanced, or Metastatic Urothelial Carcinoma: Results from ATLAS, a Phase II Open-Label Trial
ASCO GU 2020: Phase 3 Trial Results - Safety and Efficacy of Intravesical Nadofaragene Firadenovec for patients with High-Grade, BCG Unresponsive Nonmuscle Invasive Bladder Cancer (NMIBC)
ASCO GU 2020: Preliminary Results of the GETUG/AFY VESPER Trial on Toxicity and Pathological Responses
ASCO GU 2020: Discussion on the Phase II NEO-BLADE Trial and BLASST-1 in Muscle Invasive Bladder Cancer (Abstract 438 and 439)
ASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Subtyping
ASCO GU 2020: Phase II Randomized Placebo-Controlled NeoAdjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer (NEO-BLADE)
ASCO GU 2020: Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer Undergoing Cystectomy
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma - Circulating Tumor DNA
ASCO GU 2020: Best of Journals Bladder Cancer: From a Medical Oncology Perspective
ASCO GU 2020: Best of the Journals: Urothelial Carcinoma - From the Surgery Perspective
ASCO GU 2020: Options for Bacillus Calmette-Guérin (BCG) Refractory Disease
ASCO GU 2020: Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) as Perioperative Chemotherapy for Muscle Invasive Urothelial Bladder Cancer (MIUBC)
ASCO GU 2020: Management Strategies in the Face of the Bacillus Calmette-Guérin Shortage
ASCO GU 2020: Best of Journals Bladder Cancer: Radiation Oncology
ASCO GU 2020: Urothelial Carcinoma from the Perspective of a Radiation Oncologist
ASCO GU 2020: Safety and Efficacy of Intravesical Nadofaragene Firadenovec for patients with High-Grade, BCG Unresponsive Nonmuscle Invasive Bladder Cancer - Phase 3 Trial Results
ASCO GU 2020: Financial Toxicity and Quality of Life: Understanding and Improving Patient Centered Outcomes in Genitourinary Malignancies
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free